The company will soon submit its ePlex instrument and respiratory pathogen panel for US Food and Drug Administration clearance.
For the three months ended June 30, Qiagen reported net sales of $334.4 million, exceeding the Wall Street estimate of $326.8 million.
The firm's reagents and disposables business was the biggest gainer, with a 12 percent revenue increase in the quarter.
The firm completed its acquisition of Nanosphere on June 30, and received FDA clearance and CE-IVD marking for the Aries M1 system on July 6.
The company uses multiple-reaction monitoring mass spectrometry to measure exosome-bound proteins that can predict a woman's risk of preterm delivery.
In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.
Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.
Olympic athletes this summer will also undergo gene doping testing, according to Wired.
A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.